Liver metastases in the era of molecular targeted therapy: New faces of treatment response

American Journal of Roentgenology

Volumn 201, Issue 1, 2013, Pages

  Shinagare, Atul Bhanudas ^a,b   Jagannathan, Jyothi P ^a,b   Krajewski, Katherine M ^a,b   Ramaiya, Nikhil H ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atypical treatment response; Hepatic metastases; Liver metastases; Metastases; Molecular targeted therapy; Tumor response criteria

Indexed keywords

BEVACIZUMAB; CETUXIMAB; DASATINIB; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; RITUXIMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB;

ASTROCYTOMA; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE MARKER; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PANCREAS ISLET CELL TUMOR; PATIENT CARE; PRIORITY JOURNAL; RADIOLOGIST; REVIEW; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

CONTRAST MEDIA; DIAGNOSTIC IMAGING; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TREATMENT OUTCOME;

EID: 84883412076     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.9498     Document Type: Review

References (26)

1. Medscape Reference website. Khan AN, Pankhania A. Liver metastases imaging. www.emedicine. com/radio/topic394.htm. Updated November 15, 2012 Accessed June 4, 2012
2. Kim YK, Park G, Kim CS, Yu HC, Han YM. Diagnostic efficacy of gadoxetic acid-enhanced MRI for the detection and characterisation of liver metastases: comparison with multidetector-row CT. Br J Radiol 2012; 85:539-547
3. Maira F, Catania A, Candido S, et al. Molecular targeted therapy in melanoma: a way to reverse resistance to conventional drugs. Curr Drug Deliv 2012; 9:17-29
4. Metzger-Filho O, Moulin C, Awada A. Molecular targeted therapy in prevalent tumors: learning from the past and future perspectives. Curr Clin Pharmacol 2010; 5:166-177
5. Reichardt P, Reichardt A, Pink D. Molecular targeted therapy of gastrointestinal stromal tumors. Curr Cancer Drug Targets 2011; 11:688-697
6. Hudes GR, Carducci MA, Choueiri TK, et al. NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Canc Netw 2011; 9(suppl 1):S1-S29
7. Widakowich C, de Castro G Jr, de Azambuja E, Dinh P, Awada A. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007; 12:1443-1455
8. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
9. Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247
10. Baccala A Jr, Hedgepeth R, Kaouk J, Magi-Galluzzi C, Gilligan T, Fergany A. Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib. Int J Urol 2007; 14:1095-1097; discussion, 1097
11. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-2524
12. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007; 25:1760-1764
13. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25:1753-1759
14. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010; 102:803-809
15. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR 2010; 194:157-165
16. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR 2010; 194:1470-1478
17. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52-60
18. Boonsirikamchai P, Asran MA, Maru DM, et al. CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab. AJR 2011; 197:W1060-W1066
19. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368:1329-1338
20. Shankar S, vanSonnenberg E, Desai J, Dipiro PJ, Van Den Abbeele A, Demetri GD. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005; 235:892-898
21. Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Physician 2003; 68:1075-1082
22. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluation of chemotherapeutic agents. New York, NY: Columbia University Press, 1949:199-205
23. Kang H, Lee HY, Lee KS, Kim JH. Imagingbased tumor treatment response evaluation: review of conventional, new, and emerging concepts. Korean J Radiol 2012; 13:371-390
24. Kim YN, Lee HY, Lee KS, et al. Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: a new method of monitoring tumor response? Korean J Radiol 2012; 13:702-710
25. Marcus CD, Ladam-Marcus V, Cucu C, Bouché O, Lucas L, Hoeffel C. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol 2009; 72:217-238
26. Harry VN, Semple SI, Parkin DE, Gilbert FJ. Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol 2010; 11:92-102